A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.
A Cleveland Clinic team found patients with false-positive results subsequently become more involved in cancer screening programs.
A 32-year-old man presents with pain in the lower back of several weeks’ duration. What is your diagnosis?
In the US, cancer treatment is more expensive for patients younger than 65, according to a Kaiser Permanente study.
“The core message is that DLBCL can no longer be viewed as a single disease,” explained senior author Dr. Louis M. Staudt, Director of NCI’s Center for Cancer Genomics.
Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.
Researchers have developed a new model to help predict the development of breast cancer in women with atypical hyperplasia based on a breast biopsy.
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients.
In this video, Dr. Melissa Davis explains how African ancestry may play a role in breast cancer, and ways that genetics might be used to help guide treatment.
A 23-year-old with no relevant prior medical history presents with pain in the right leg. What is your diagnosis?
Melanoma patients who are married tend to present at earlier stages of the disease than those who are not married, divorced, or widowed; marital status was also associated with the likelihood of undergoing SLNB.
In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC.
A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.